The lancet oncology
-
The lancet oncology · Jul 2022
Randomized Controlled TrialTumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis.
Tumour response heterogeneity to treatment is common across different foci in the same patient with cancer. However, the effect of heterogeneity on clinical outcome remains unclear. Here, we developed a quantitative assessment of tumour response heterogeneity and explored the correlation of tumour response heterogeneity with the clinical outcome. ⋯ National Natural Science Foundation of China (grant 82072565) and Bejing Xisike Clinical Oncology Research Foundation (grant Y-2019AZZD-0386).
-
The lancet oncology · Jul 2022
Randomized Controlled TrialHigh incidence of severe pain is associated with low opioid availability in patients with advanced cancer: a nationwide questionnaire survey in Japan.
Opioid availability for the palliative care of patients with advanced cancer is increasing globally. However, opioid consumption in Japan is still extremely low compared with that in other countries. We investigated the current situation of pain control and opioid consumption in patients with advanced cancer in Japan. ⋯ This study was funded by the authors and by Shionogi (Osaka, Japan), Nippon Zoki Pharmaceutical (Osaka, Japan), and Heartfelt (Kumamoto, Japan).
-
The lancet oncology · Jul 2022
Availability of essential medicines for children with cancer in Sri Lanka: a prospective cohort study.
The WHO Model List of Essential Medicines for children (2019 version) contains 39 antineoplastic and supportive medicines deemed essential for the successful treatment of children with cancer. The availability of these medicines varies across countries, but most reports are retrospective or short term. This study tracked the availability of these medicines in Sri Lanka's only treatment centre for childhood cancer, the National Cancer Institute of Sri Lanka, over 1 year, and examined initial mitigation strategies and implications. ⋯ None.
-
The lancet oncology · Jul 2022
Prognostic factors in curative intent stage I lung adenocarcinoma: a retrospective hospital-based cohort study.
Radiotherapy or surgery, depending on hospital specialisation status (ie, High Complexity Centres in Oncology [HCCO; hospitals with infrastructure, technology, physical facilities, equipment, and human resources suitable for highly complex specialised assistance], or Partial Hospital Complexity Centres in Oncology [PHCCO; hospitals with infrastructures and specialisation similar to that of HCCOs, but doing diagnosis and treatment for common cancers only], as per nomenclature used in Brazil), can increase overall survival in patients diagnosed with lung adenocarcinoma. However, many patients do not accept surgery because of comorbidities and personal preferences. In addition, the long time between diagnosis and treatment and the qualification of the hospital specialisation status might affect the outcomes for patients with lung adenocarcinoma. The aim of this study was to evaluate prognostic factors of overall survival in patients with stage I lung cancer adenocarcinoma diagnosed in the state of São Paulo, Brazil. ⋯ Oncocentro Foundation and Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
-
The lancet oncology · Jul 2022
Impact of geospatial barriers on breast cancer care in Haiti: a retrospective cohort study.
Although geospatial barriers to cancer care are recognised, data quantifying their magnitude and impact on treatment and outcomes in low-income and middle-income countries are scarce. The objective of this study was to describe the geospatial distribution of patients receiving care for breast cancer at a tertiary hospital in Haiti. ⋯ Center for Global Cancer Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.